Comment: International Arbitration from the Corporate Perspective - WAMR 2010 Vol. 4, No. 2
Elpidio ("PD") Villarreal is Senior Vice President -
Global Litigation. Prior to joining GSK, PD was
Vice President for Litigation at Schering Plough
from 2005 to 2009. From 1995 to 2005, PD was
Senior Litigation Counsel for the General Electric
Company in Fairfield, Connecticut. Before GE, PD
was a partner at the Sonnenschein firm in Chicago. He is a 1982
graduate of Columbia University (Magna Cum Laude, Phi Beta
Kappa) and a 1985 graduate of the Yale Law School. He clerked
on the United States Court of Appeals for the Seventh Circuit in
Chicago for the Late Honorable Luther M. Swygert.
Originally from World Arbitration And Mediation Review (WAMR)
Preview Page
Comment
INTERNATIONAL ARBITRATION FROM THE
CORPORATE PERSPECTIVE
Elpidio ("PD") Villarreal*
I. INTRODUCTION
My purpose is to give a corporate perspective on the
contemplated changes to the arbitration system in the United
States. Actually, it is not that difficult a job because, to the extent
that this is on the radar screen of corporate counsel (and it is not
on the radar screen of all corporate counsel), the sentiment is
essentially uniform that this is a very bad idea, and that the notion
of making significant, potentially far-reaching changes to the
arbitration system in this country is untimely and completely
unnecessary. Whether this is a good idea looks very different
depending on your perspective, I suppose. But as someone whose
job it is to defend the global litigation risk challenges of a large
multinational corporation, this does not look like a particularly
good idea. There is growing opposition within corporate circles,
chambers of commerce, and other legal reform groups. Over the
coming months, they will be mounting a challenge to some of the
more far-reaching aspects of the legislative bills that are under
consideration.
From a corporate perspective , arbitration in this country has
had its shortcomings and critics. But all those shortcomings pale
in comparison to the shortcomings of litigation, and not just for
corporate defendants like GlaxoSmithKline ("GSK"), my client, but
really also for plaintiffs. The notion that the choice is between an
arbitration system that is unfair to plaintiffs versus a litigation
system that is paradise for plaintiffs is, I think, naïve. My own
sense is that, in fact, the current litigation system is not all that